Breen CT, Chao J, Mehra S, et al. - In the present study, the researchers sought to explain disease characteristics and treatment and to examine survival and mortality for extranodal mantle cell lymphoma (MCL) of the head and neck. Patients with extranodal MCL were identified from the Surveillance, Epidemiology, and End Results 18 Registries (2000-2015), excluding primary sites in the salivary glands, eye, and adnexa. With a median follow-up of 58 months, 509 patients met the criteria for descriptive analysis and 294 patients met the criteria for survival analysis. The oropharynx, nasopharynx, and oral cavity were the most common sites for MCL. Chemotherapy alone was the most common treatment, followed by chemoradiation therapy and radiation therapy alone. The most common subsite of head and neck MCLs is the oropharynx, followed by the nasopharynx. Primary head and neck MCLs seem to present at an earlier stage than MCLs of other regions. In particular, laryngeal and hypopharyngeal MCLs can manifest as stage I or II disease.